Mitochondrial Dysfunction in a Long-term Rodent Model of Sepsis and Organ Failure
Overview
Authors
Affiliations
Although sepsis is the major cause of mortality and morbidity in the critically ill, precise mechanism(s) causing multiorgan dysfunction remain unclear. Findings of impaired oxygen utilization in septic patients and animals implicate nitric oxide-mediated inhibition of the mitochondrial respiratory chain. We recently reported a relationship between skeletal muscle mitochondrial dysfunction, clinical severity, and poor outcome in patients with septic shock. We thus developed a long-term, fluid-resuscitated, fecal peritonitis model utilizing male Wistar rats that closely replicates human physiological, biochemical, and histological findings with a 40% mortality. As with humans, the severity of organ dysfunction and eventual poor outcome were associated with nitric oxide overproduction and increasing mitochondrial dysfunction (complex I inhibition and ATP depletion). This was seen in both vital (liver) and nonvital (skeletal muscle) organs. Likewise, histological evidence of cell death was lacking, suggesting the possibility of an adaptive programmed shutdown of cellular function. This study thus supports the hypothesis that multiorgan dysfunction induced by severe sepsis has a bioenergetic etiology. Despite the well-recognized limitations of laboratory models, we found clear parallels between this long-term model and human disease characteristics that will facilitate future translational research.
Connexin hemichannels and early atrophic signaling in muscle during sepsis.
Balboa E, Saavedra F, Cea L, Vargas A, Regueira T, Saez J Front Physiol. 2025; 16:1514769.
PMID: 40066286 PMC: 11891358. DOI: 10.3389/fphys.2025.1514769.
Mitochondrial dysfunction in sepsis: mechanisms and therapeutic perspectives.
Hu D, Sheeja Prabhakaran H, Zhang Y, Luo G, He W, Liou Y Crit Care. 2024; 28(1):292.
PMID: 39227925 PMC: 11373266. DOI: 10.1186/s13054-024-05069-w.
Wang Z, Xu J, Mo L, Zhan R, Zhang J, Liu L Drug Des Devel Ther. 2024; 18:3005-3023.
PMID: 39050796 PMC: 11268596. DOI: 10.2147/DDDT.S465713.
Shu L, Huo B, Yin N, Xie H, Erbu A, Ai M Pharmacol Res Perspect. 2024; 12(4):e1236.
PMID: 39049495 PMC: 11269369. DOI: 10.1002/prp2.1236.
CD5L as a promising biological therapeutic for treating sepsis.
Oliveira L, Silva M, Gomes A, Santos R, Cardoso M, Novoa A Nat Commun. 2024; 15(1):4119.
PMID: 38750020 PMC: 11096381. DOI: 10.1038/s41467-024-48360-8.